Intra-Cellular Therapies, Inc.
ITCI
株式のランク
#1690
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
株価
$131.87
最終同期: 2025-04-02
時価総額
$12.68B
変化（1日）
0.00%
変化（1年）
0.00%
国
US
取引 Intra-Cellular Therapies, Inc. (ITCI)
カテゴリー
Healthcare
Intra-Cellular Therapies, Inc.（ITCI）の収益
Dec 2024 時点の収益 TTM: $680.64M
Intra-Cellular Therapies, Inc. の最新の財務報告によると、現在の収益 (TTM) は $680.64M です。2023 年には $464.37M の収益があり、これは 2022 年の $249.13M と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Intra-Cellular Therapies, Inc. の収益履歴（2013 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $680.64M | -0.03% |
| 2024 | $680.85M | 46.62% |
| 2023 | $464.37M | 86.40% |
| 2022 | $249.13M | 204.91% |
| 2021 | $81.71M | 262.65% |
| 2020 | $22.53M | 37,071.49% |
| 2019 | $60.61K | 0.00% |
| 2018 | 0.00 | -100.00% |
| 2017 | $245.84K | -25.66% |
| 2016 | $330.70K | 261.96% |
| 2015 | $91.36K | -84.17% |
| 2014 | $577.30K | -78.91% |
| 2013 | $2.74M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 871.39% |
IN
|
